COVID-19 vaccine remains months away but officials look to speed up approval process - Global News | Canada News Media
Connect with us

Business

COVID-19 vaccine remains months away but officials look to speed up approval process – Global News

Published

 on


OTTAWA — Health Canada is in talks with all of the vaccine developers that signed supply deals with the federal government to kick-start the approval process and get COVID-19 vaccines to Canadians as soon as possible.

Read more:
University of Waterloo research considers who should get COVID-19 vaccine first

In the last two months, Public Services and Procurement Canada has signed deals with the makers of six COVID-19 vaccines, that will see Canada spend more than $1 billion to get guaranteed access to between 20 million and 76 million doses of each one if they are approved.

All have to complete clinical trials and be deemed both safe and effective at preventing or lessening the effect of COVID-19, but before they can be used here, Health Canada also has to decide they meet its standards as well.

Story continues below advertisement

Normally the Health Canada review would happen after all trials are over, but Dr. Supriya Sharma, the chief medical adviser at Health Canada, said given the heightened need for a COVID-19 vaccine, Health Canada is trying to get the regulatory process done at the same time as the final trials are being completed.

“We’re still talking about months not weeks in terms of timeline and really the ultimate length of the review depends on the data,” she said.

“It’s always grounded in the scientific assessment.”






4:39
When can Canadians expect a COVID-19 vaccine?


When can Canadians expect a COVID-19 vaccine?

Still, she says normally the regulatory process takes more than a year, and with added resources and expedited timelines, she thinks the first vaccine will be approved in Canada in “months, not years.”

[ Sign up for our Health IQ newsletter for the latest coronavirus updates ]

Thus far AstraZeneca is the only company that has applied for Canadian approval, submitting the application and its first scientific results on Oct. 2.

Story continues below advertisement

“We are in discussions with other companies about whether or not they’re ready to submit as well,” she said.

Five of the six, including AstraZeneca’s candidate, are now in the third and final phase of clinical trials, and most are expecting their results by the end of the year.

Read more:
How many Canadians have the new coronavirus? Total number of confirmed cases by region

AstraZeneca, Moderna, NovaVax, Johnson and Johnson and Pfizer are also in Phase 3 trials, while GlaxoSmithKline and Sanofi’s vaccine is in Phase 2.

No vaccine has completed Phase 3 trials yet anywhere in the world.

New vaccines or drugs go through multiple stages of trials on humans, looking first to see if they are safe and cause no serious adverse reactions. Each phase adds more people, with usually fewer than a dozen to start, rising to tens of thousands by Phase 3.

Sharma said the international consensus, with which Health Canada agrees, is that no vaccine will be approved unless it is at least 50 per cent effective at preventing COVID-19.






1:40
Canada signs new coronavirus vaccine deals


Canada signs new coronavirus vaccine deals

She said, however, the results of the trials of the most promising vaccines show much higher effectiveness than that.

Story continues below advertisement

A recommendation on which Canadians would be prioritized to get vaccinated first is expected in a few weeks from the National Advisory Committee on Immunization.

Ultimately provinces and territories will decide who they will prioritize for the vaccine, as it is provincial and territorial health systems that will run vaccination programs in their jurisdictions.

Sharma said to be effective at slowing the spread of COVID-19, between 60 and 70 per cent of Canadians will need immunity, either naturally because they have had COVID-19, or because of a vaccine.

It is not yet known yet how long immunity lasts for people who have been infected with COVID-19.

© 2020 The Canadian Press

Let’s block ads! (Why?)



Source link

Business

Restaurant Brands reports US$357M Q3 net income, down from US$364M a year ago

Published

 on

 

TORONTO – Restaurant Brands International Inc. reported net income of US$357 million for its third quarter, down from US$364 million in the same quarter last year.

The company, which keeps its books in U.S. dollars, says its profit amounted to 79 cents US per diluted share for the quarter ended Sept. 30 compared with 79 cents US per diluted share a year earlier.

Revenue for the parent company of Tim Hortons, Burger King, Popeyes and Firehouse Subs, totalled US$2.29 billion, up from US$1.84 billion in the same quarter last year.

Consolidated comparable sales were up 0.3 per cent.

On an adjusted basis, Restaurant Brands says it earned 93 cents US per diluted share in its latest quarter, up from an adjusted profit of 90 cents US per diluted share a year earlier.

The average analyst estimate had been for a profit of 95 cents US per share, according to LSEG Data & Analytics.

This report by The Canadian Press was first published Nov. 5, 2024.

Companies in this story: (TSX:QSR)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Electric and gas utility Fortis reports $420M Q3 profit, up from $394M a year ago

Published

 on

 

ST. JOHN’S, N.L. – Fortis Inc. reported a third-quarter profit of $420 million, up from $394 million in the same quarter last year.

The electric and gas utility says the profit amounted to 85 cents per share for the quarter ended Sept. 30, up from 81 cents per share a year earlier.

Fortis says the increase was driven by rate base growth across its utilities, and strong earnings in Arizona largely reflecting new customer rates at Tucson Electric Power.

Revenue in the quarter totalled $2.77 billion, up from $2.72 billion in the same quarter last year.

On an adjusted basis, Fortis says it earned 85 cents per share in its latest quarter, up from an adjusted profit of 84 cents per share in the third quarter of 2023.

The average analyst estimate had been for a profit of 82 cents per share, according to LSEG Data & Analytics.

This report by The Canadian Press was first published Nov. 5, 2024.

Companies in this story: (TSX:FTS)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Thomson Reuters reports Q3 profit down from year ago as revenue rises

Published

 on

 

TORONTO – Thomson Reuters reported its third-quarter profit fell compared with a year ago as its revenue rose eight per cent.

The company, which keeps its books in U.S. dollars, says it earned US$301 million or 67 cents US per diluted share for the quarter ended Sept. 30. The result compared with a profit of US$367 million or 80 cents US per diluted share in the same quarter a year earlier.

Revenue for the quarter totalled US$1.72 billion, up from US$1.59 billion a year earlier.

In its outlook, Thomson Reuters says it now expects organic revenue growth of 7.0 per cent for its full year, up from earlier expectations for growth of 6.5 per cent.

On an adjusted basis, Thomson Reuters says it earned 80 cents US per share in its latest quarter, down from an adjusted profit of 82 cents US per share in the same quarter last year.

The average analyst estimate had been for a profit of 76 cents US per share, according to LSEG Data & Analytics.

This report by The Canadian Press was first published Nov. 5, 2024.

Companies in this story: (TSX:TRI)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Trending

Exit mobile version